Oraya Therapeutics has completed patient enrolment for its INTREPID clinical trial of the IRay stereotactic radiotherapy system in Europe.
The study is the first sham-controlled, double-masked trial to evaluate the effectiveness and safety of radiation therapy in conjunction with standard of care anti-VEGF injections for the treatment of wet age-related macular degeneration.
The multi-national study will involve 226 patients and be performed at sites in Austria, the Czech Republic, Germany, Italy and the UK.
The efficacy results of the study are expected to be available from second quarter of 2012.
Oraya Therapeutics CEO Jim Taylor said that the company plans to conduct a larger study at the beginning of 2012.
IRay delivers a highly-localised dose of X-ray radiation to the macula using a proprietary positioning system, targeting algorithm and special contact lens for eye stabilisation, improving vision outcomes and tracking.
